Shares of Novavax, Inc. (NVAX) are currently losing nearly 18% on Tuesday morning.
NVAX is currently trading at $98.27, down $20.99 or 17.60%, on the Nasdaq.
On Monday, Novavax announced that the first volunteers have been enrolled in the phase 2 portion of its ongoing clinical trial to evaluate the immunogenicity and safety of NVX-CoV2373, the company's COVID-19 vaccine candidate.
In the phase 1 portion of the phase 1/2 clinical trial, conducted in Australia, NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera.
NVX-CoV2373 is a stable, prefusion protein made using proprietary nanoparticle technology and includes Novavax's proprietary Matrix-M adjuvant.
Meanwhile, AstraZeneca on Tuesday announced that it has started a clinical trial of a drug to help prevent and treat Covid-19, with the first volunteers already receiving doses.
The Phase I trial of AZD7442 will evaluate the safety, tolerability and of the durg. It will include up to 48 healthy participants in the UK aged 18 to 55 years.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.